Cubist Systematic Strategies, LLC Morphic Holding, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $182,154 - $329,555	5,306 Added 465.44%	6,446 $369,000
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $239,057 - $447,509	-9,191 Reduced 88.97%	1,140 $42,000
Q4 2022 Feb 14, 2023	SELL	$24.14 - $30.37 $1.23 Million - $1.55 Million	-50,944 Reduced 83.14%	10,331 $276,000
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $496,040 - $744,618	22,314 Added 57.27%	61,275 $1.73 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $566,024 - $1.23 Million	28,674 Added 278.74%	38,961 $845,000
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $146,087 - $209,640	-4,030 Reduced 28.15%	10,287 $413,000
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $154,517 - $234,686	3,571 Added 33.23%	14,317 $678,000
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $381,435 - $480,262	-7,115 Reduced 39.84%	10,746 $609,000
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $436,587 - $628,713	9,674 Added 118.16%	17,861 $1.03 Million
Q1 2021 May 17, 2021	SELL	$29.77 - $84.85 $1,458 - $4,157	-49 Reduced 0.59%	8,187 $518,000
Q4 2020 Feb 16, 2021	BUY	$25.66 - $34.55 $211,335 - $284,553	8,236 New	8,236 $276,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.